A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small-cell lung cancer (NSCLC)
| Autor: | F. Pannuti, L. Busutti, Andrea Martoni, M. Casadio, M. Guaraldi |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male medicine.medical_specialty Lung Neoplasms medicine.medical_treatment non-small cell lung cancer (NSCLC) Phases of clinical research Gastroenterology Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Epirubicin Chemotherapy Ejection fraction Performance status Cumulative dose business.industry Hematology Middle Aged medicine.disease Surgery Regimen Oncology Female Cisplatin business medicine.drug |
| Zdroj: | Annals of Oncology. 3:864-866 |
| ISSN: | 0923-7534 |
| Popis: | Summary Thirty-seven patients with unresectable NSCLC received epirubicin (EPI) as i.v. bolus at the dose of 120 mg/sm + cisplatinum (CP) at the dose of 60 mg/sm every 28 days up to the maximum cumulative dose of 840 mg/sm of EPI. Of 35 evaluable patients, 19 (54%) (95% confidence limits: 37%–71%) achieved PR for a median duration of 10 months (range: 2–21). The majority of responsive patients experienced improvement in performance status, related-disease symptoms and body weight. Grades 3–4 leukopenia occurred in 42% of the patients. In five patients there was a >10% reduction in the left ventricular ejection fraction as calculated by radionuclide angiocardiography. None of these patients suffered from cardiac symptoms. The median survival was 9 months (range 2–26). This study shows that inclusion of HD-EPI in a combination regimen contributes to obtaining a high remission rate in advanced NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|